Edgar Filing: McHutchison John G

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â McHutchison John G

2. Date of Event Requiring Statement (Month/Day/Year)
04/23/2018

3. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES INC [GILD]

(Last)

(First)

(Middle)

GILEAD SCIENCES, INC.,Â 333 LAKESIDE DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Scientific Off/HeadR&D

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

FOSTER CITY,Â CAÂ 94404

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22,906	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Non-qualified Stock Option (Right to Buy)	Â ⁽¹⁾	07/22/2020	Common Stock	19,950	$ 16.89	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	01/26/2022	Common Stock	16,850	$ 24.295	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/01/2023	Common Stock	29,710	$ 40.56	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/01/2024	Common Stock	42,290	$ 80.65	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/01/2025	Common Stock	51,690	$ 104.83	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/01/2026	Common Stock	58,950	$ 84.05	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/02/2027	Common Stock	63,590	$ 72.25	D	Â
Non-qualified Stock Option (Right to Buy)	Â ⁽²⁾	02/01/2028	Common Stock	62,910	$ 83.49	D	Â
Restricted Stock Unit	Â ⁽³⁾	Â ⁽³⁾	Common Stock	2,930	$ ⁽⁴⁾	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
McHutchison John G GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY,Â CAÂ 94404	Â	Â	Â Chief Scientific Off/HeadR&D	Â

Signatures

/s/ Marissa Song by Power of Attorney for John G McHutchison		04/27/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
(2)	The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
(3)	The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
(4)	Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.